top bottom line guidanc light
report revenu significantli consensu
adjust ep beat consensu strong product sale full year
guidanc adjust ep came light compar
consensu continu share repurchas program buy
back adjust non-gaap ep po
multipl vs prior in-lin major biopharma peer
light new guidanc reiter buy strong fundament
top-line beat driven neulasta aimovig
amgn top-line beat driven number product none
neulasta neulasta sale beat consensu driven volum
growth includ purchas us biomed advanc research
develop author expect neulasta sale declin biosimilar
competitor gain market share net price decreas aimovig also significantli
outperform consensu bring vs launch remain
strong though note prior period account estim prolia
xgeva beat consensu continu key driver top-line growth us repatha
sale also top estim driven double-digit volum growth partial off-set
lower net sell price enbrel sale in-lin estim vs
consensu strong perform newer product aimovig repatha prolia/xgeva
key offset declin neulasta enbrel potenti sensipar
depend litig play due competit
continu focu capit alloc
given transit legaci product revenu declin earli launch new
product investor wonder plan util balanc sheet
cash flow although financi wherewith consumm larg
scale acquisit sens manag disciplin high hurdl
creat sharehold valu base case assum return excess
capit higher dividend share buyback
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu nearli
buy rate base new product launch
anticip biosimilar launch
help drive top-lin growth strong
cash posit also allow addit share
buyback dividend payment transform
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
